Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | QDPR | P09417 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12522315 | 0.90 | RAB9A (0.40) | CYP4F2CYP4A11EPHX2EPHX1MEN1 | |
| SCHEMBL19265714 | 0.90 | RAB9A (0.40) | CYP4F2CYP4A11EPHX2EPHX1MEN1 | |
| SCHEMBL19049584 | 0.86 | KMT2A (0.39) | MEN1KMT2AMAPTKDM4E | |
| SCHEMBL797393 | 0.84 | KMT2A (0.42) | MEN1KMT2AMAPTKDM4E | |
| SCHEMBL19604766 | 0.82 | F10 (0.42) | CYP4F2CYP4A11EPHX2EPHX1F10 | |
| SCHEMBL17975154 | 0.82 | HDAC3 (0.43) | CYP4F2CYP4A11EPHX2EPHX1F10 | |
| SCHEMBL12801686 | 0.81 | AKR1C3 (0.48) | EPHX2EPHX1MEN1KMT2A | |
| SCHEMBL12522184 | 0.81 | KMT2A (0.43) | MEN1KMT2A | |
| SCHEMBL25594470 | 0.81 | ALDH1A1 (0.46) | CYP4F2CYP4A11EPHX2EPHX1F10 | |
| SCHEMBL19601422 | 0.81 | SMN1; SMN2 (0.49) | CYP4F2CYP4A11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026083-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | RIBON THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023006097-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | 海创药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| EP-4116301-A1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2023-01-11 | — | — | EP | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3455216-B1 | PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AS AOC3 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-11-04 | — | — | EP | disclosed |
| WO-2020021064-A1 | SUBSTITUTED QUINAZOLINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | DOMAIN THERAPEUTICS (FR) | 2020-01-30 | — | — | WO | disclosed |
| EP-2427195-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9926292-B2 | Pyridinyl derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-7491748-B2 | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318703-A1 | CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | PTGER2, PTGER4, PTGER1 | CYP4F2 547/4885CYP4A11 343/4885EPHX2 289/4885 |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | CYP4F2 2577/4885CYP4A11 3688/4885EPHX2 1504/4885 |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | CYP4F2 1156/4885CYP4A11 2945/4885EPHX2 2402/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | CYP4F2 3795/4885CYP4A11 2398/4885EPHX2 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.